We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Smiths Group Plc | LSE:SMIN | London | Ordinary Share | GB00B1WY2338 | ORD 37.5P |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
1,748.00 | 1,749.00 | 1,751.00 | 1,698.00 | 1,698.00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Srch,det,nav,guid,aero Sys | 3.04B | 231M | 0.6647 | 26.30 | 6B |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
16:35:22 | AT | 696 | 1,744.00 | GBX |
Date | Time | Source | Headline |
---|---|---|---|
26/7/2024 | 07:00 | UK RNS | Smiths Group PLC Transaction in Own Shares |
25/7/2024 | 07:00 | UK RNS | Smiths Group PLC Transaction in Own Shares |
24/7/2024 | 07:00 | UK RNS | Smiths Group PLC Transaction in Own Shares |
23/7/2024 | 07:00 | UK RNS | Smiths Group PLC Transaction in Own Shares |
22/7/2024 | 07:00 | UK RNS | Smiths Group PLC Transaction in Own Shares |
19/7/2024 | 10:36 | UK RNS | Smiths Group PLC Transaction in Own Shares |
17/7/2024 | 10:03 | ALNC | IN BRIEF: Smiths Group banks USD152 million from ICU Medical shares |
17/7/2024 | 07:00 | UK RNS | Smiths Group PLC Smiths sells 1.2m shares in ICU Medical Inc |
12/7/2024 | 07:00 | UK RNS | Smiths Group PLC Transaction in Own Shares |
11/7/2024 | 07:00 | UK RNS | Smiths Group PLC Transaction in Own Shares |
Smiths (SMIN) Share Charts1 Year Smiths Chart |
|
1 Month Smiths Chart |
Intraday Smiths Chart |
Date | Time | Title | Posts |
---|---|---|---|
17/7/2024 | 10:03 | Smiths Group _ ACTIVE INVESTORS CLUB (SMIN) | 240 |
22/4/2016 | 13:30 | Smiths Group | 221 |
31/1/2006 | 17:40 | Potential in these troubled times ? | 43 |
15/12/2005 | 10:55 | Numis upgrades | 1 |
26/9/2003 | 14:48 | Company about to face massive lawsuit re leaking sensitive info? | 1 |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|---|---|---|---|
2024-07-26 15:35:22 | 1,744.00 | 696 | 12,138.24 | AT |
2024-07-26 15:35:22 | 1,744.00 | 4,894 | 85,351.36 | AT |
2024-07-26 15:35:22 | 1,744.00 | 221,154 | 3,856,925.76 | UT |
2024-07-26 15:34:22 | 1,741.42 | 19,000 | 330,870.60 | O |
2024-07-26 15:29:40 | 1,748.00 | 15 | 262.20 | O |
Top Posts |
---|
Posted at 26/7/2024 09:20 by Smiths Daily Update Smiths Group Plc is listed in the Srch,det,nav,guid,aero Sys sector of the London Stock Exchange with ticker SMIN. The last closing price for Smiths was 1,726p.Smiths currently has 347,513,730 shares in issue. The market capitalisation of Smiths is £6,074,540,000. Smiths has a price to earnings ratio (PE ratio) of 26.30. This morning SMIN shares opened at 1,698p |
Posted at 17/7/2024 10:03 by philanderer Smiths Group plc confirms that it has sold 1.2m shares in ICU Medical Inc ('ICU Medical'), representing approximately 4.9% of ICU Medical's issued share capital. Smiths will receive net proceeds of c.$152m (£117m) from the sale which will be used for general corporate purposes.Smiths continues to hold 0.47m shares in ICU Medical representing approximately 1.92% of ICU Medical's issued share capital. |
Posted at 16/7/2024 23:47 by philanderer The TelegraphQuestor: We’re still bullish about this FTSE 100 stock despite disappointing returns Questor says: buy Ticker: SMIN Share price at close: £17.51 |
Posted at 11/4/2024 10:46 by philanderer HSBC raises Smiths Group to 'buy' (hold) - price target 2,000 (1,875) pence |
Posted at 26/3/2024 14:37 by philanderer Goldman Sachs raises Smiths Group price target to 2,250 (2,220) pence - 'buy' |
Posted at 12/3/2024 11:25 by philanderer Goldman Sachs cuts Smiths Group price target to 2,220 (2,240) pence - 'buy' |
Posted at 08/12/2023 10:09 by philanderer JPMorgan cuts Smiths Group price target to 1,910 (1,980) pence - 'overweight' |
Posted at 02/12/2023 20:04 by philanderer Friday 11:41am: Smiths climbs after 'informative' CMDSmiths Group (LSE:SMIN) has climbed 1.0% after its Capital Markets Day yesterday. Analysts explained the presentation was focused on John Crane, the group’s largest division. Liberum said while there were no changes to financial guidance, it re-affirmed its positive investment thesis. The presentation highlighted the resilience of John Crane’s high margins, showed how energy transition is an opportunity for John Crane, and that Smiths has the capacity to invest to keep or grow share as energy markets transition. Overall, Liberum said confidence in its John Crane estimates was reinforced by the upbeat demand outlook as detailed in the management presentations and as supported by the current strong orderbook. It has ‘buy’ rating and 2,150p price target. Barclays decsribed the event as “informative,& Barclays has an ‘overweight proactiveinvestors.c |
Posted at 27/9/2023 14:10 by essentialinvestor Phil, enjoy.Daisy, SMIN usually gets knocked on risk off markets, economic slowdown fears etc. The multiple now looks reasonable, particularly given low gearing - but a lot is getting cheaper in this market ATM. |
Posted at 27/9/2023 11:56 by philanderer Morning EI, yes , managed to exit VID @ 580p. On holiday in Sesimbra, Portugal at the moment but heard the strike settlement news on BBC World service and sold my holding at the market open the following morning.Disappointing reaction to SMIN results. |
Posted at 28/9/2021 21:34 by essentialinvestor We lose £110 million on pre tax (annually) from the sale of Smiths Medical - a large chunk of profitability.On the plus side should be 10% less shares in issue - approx 12.6% on the current SMIN share price. At least a £15 million annual interest saving on lower net debt, plus a £15 million annual saving on lower pension contributions from FY '22. Net debt should fall to somewhere around £400 million, or under. $500 plus value in the 10% of ICU shares - at their current SP think it's nearer $600 million approx. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions